Key Highlights

  • Standard BioTools shares traded at $0.85, down 5.02% on the day.
  • TLN-121 Phase 1 data showed an 84% overall response rate in relapsed or refractory lymphomas.
  • The complete response rate was 32%, with no observed dose-limiting toxicities.
  • TLN-121 is part of the company's pending merger with Treeline Biosciences, Inc.

Standard BioTools Inc. (NASDAQ: LAB) shares traded at $0.85, down 5.02% on the day, as the company advances two Phase 1 oncology programs, TLN-121 and TLN-372, amid its pending merger with Treeline Biosciences, Inc.

What Happened

TLN-121, being studied in relapsed or refractory lymphomas, showed an overall response rate of 84%, a complete response rate of 32%, and no observed dose-limiting toxicities in its Phase 1 study. A Phase 1 data update for TLN-121 is planned for 2027, following completion of the merger with Treeline Biosciences, noted July 20, 2026.

TLN-372, a separate Phase 1 program targeting KRAS mutant solid tumors, is ongoing, with data also planned for 2027.

Market Reaction

Shares traded down 5.02% at $0.85, with Standard BioTools' market capitalization at approximately $331.81 million, according to the disclosed pipeline database.

Both TLN-121 and TLN-372 share the same disclosed market capitalization figure, reflecting that they are both programs within the same company.

Outlook

Data updates for both TLN-121 and TLN-372 are planned for 2027, with the TLN-121 update specifically tied to completion of the company's merger with Treeline Biosciences, Inc.

What did Standard BioTools' Phase 1 TLN-121 data show?

An overall response rate of 84%, a complete response rate of 32%, and no observed dose-limiting toxicities in relapsed or refractory lymphomas.

What is TLN-372 being studied for?

TLN-372 is an ongoing Phase 1 program targeting KRAS mutant solid tumors.

How does the Treeline Biosciences merger relate to these programs?

A Phase 1 data update for TLN-121 is planned for 2027, following completion of the merger with Treeline Biosciences, Inc.